

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hour per response: 4.0

1. Issuer's Identity		
CIK (Filer ID Number)	Previous Name(s) None	Entity Type
0001173281	BBM HOLDINGS, INC.	© Corporation
Name of Issuer	PRIME RESOURCE INC	C Limited Partnership
Ohr Pharmaceutical Inc		C Limited Liability Company
Jurisdiction of Incorporation/Organization		C General Partnership
DELAWARE		C Business Trust
Year of Incorporation/Organization	n	C Other
♥ Over Five Years Ago		
C Within Last Five Years (Specify Year)		
C Yet to Be Formed		



3. Related Persons						
Last Name	First Name		Middle Name			
Greenstein Ira]			
	li a	G. 4433				
Street Address 1		Street Address 2				
c/o Ohr Pharmaceutical, Inc.		489 Fifth Avenu	e, 28th Floor			
City	State/Province/C	Country	ZIP/Postal Code			
New York	NEW YORK		10017			
Relationship:						
Clarification of Response (if Necessary)						
Cimilionity of Itespoins (II I recessing	,,					
Last Name	First Name		Middle Name			
Taraporewala	Irach					
Street Address 1		Street Address 2				
c/o Ohr Pharmaceutical, Inc.		489 Fifth Avenu	e, 28th Floor			
City	City State/Province/Country ZIP/Postal Code					
New York	NEW YORK		10017			
			-			
Relationship: Execut	tive Officer	Director	Promoter			

Last Name	First Name		Middle Name				
Hirschman	Orin						
Street Address 1		Street Address 2	_				
c/o Ohr Pharmaceutical, Inc.		489 Fifth Avenu	ne, 28th Floor				
City	State/Province/C	Country	ZIP/Postal Code				
New York	NEW YORK		10017				
Relationship:	ive Officer	□ Director	Promoter				
Clarification of Response (if Necessary)							
Last Name	First Name		Middle Name				
Riedhammer	Thomas						
Street Address 1		Street Address 2					
c/o Ohr Pharmaceutical, Inc.		489 Fifth Avenu	ie, 28th Floor				
City	State/Province/C	Country	ZIP/Postal Code				
New York	NEW YORK		10017				
Relationship: Execut	ive Officer	Director	Promoter				
Clarification of Response (if Necessary Last Name	First Name		Middle Name				
Almenoff	June						
Almenoff Street Address 1	June	Street Address 2					
	June	Street Address 2	ie, 28th Floor				
Street Address 1 c/o Ohr Pharmaceutical, Inc.		489 Fifth Avenu	ne, 28th Floor ZIP/Postal Code				
Street Address 1	State/Province/C	489 Fifth Avenu	·				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City	State/Province/C	489 Fifth Avenu	ZIP/Postal Code				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City	State/Province/C	489 Fifth Avenu	ZIP/Postal Code				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York	State/Province/C NEW YORK ive Officer	489 Fifth Avenu	ZIP/Postal Code				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York Relationship: Execut	State/Province/C NEW YORK ive Officer	489 Fifth Avenu	ZIP/Postal Code				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York Relationship: Execut Clarification of Response (if Necessary	State/Province/C NEW YORK ive Officer	489 Fifth Avenu	ZIP/Postal Code 10017 Promoter				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York Relationship: Execut Clarification of Response (if Necessary Last Name	State/Province/C NEW YORK ive Officer)	489 Fifth Avenu	ZIP/Postal Code 10017 Promoter				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York Relationship: Execut Clarification of Response (if Necessary Last Name Backenroth	State/Province/C NEW YORK ive Officer)	489 Fifth Avenu	ZIP/Postal Code 10017 Promoter Middle Name				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York Relationship: Execut Clarification of Response (if Necessary Last Name Backenroth Street Address 1	State/Province/C NEW YORK ive Officer)	A89 Fifth Avenu Country Director Street Address 2 489 Fifth Avenu	ZIP/Postal Code 10017 Promoter Middle Name				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York Relationship: Execut Clarification of Response (if Necessary Last Name Backenroth Street Address 1 c/o Ohr Pharmaceutical, Inc.	State/Province/C NEW YORK ive Officer First Name Sam	A89 Fifth Avenu Country Director Street Address 2 489 Fifth Avenu	ZIP/Postal Code 10017 Promoter Middle Name 1e, 28th Floor				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York Relationship: Execut Clarification of Response (if Necessary Last Name Backenroth Street Address 1 c/o Ohr Pharmaceutical, Inc. City	State/Province/C NEW YORK ive Officer First Name Sam State/Province/C	A89 Fifth Avenu Country Director Street Address 2 489 Fifth Avenu	ZIP/Postal Code 10017 Promoter Middle Name 1c, 28th Floor ZIP/Postal Code				
Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York Relationship: Execut Clarification of Response (if Necessary Last Name Backenroth Street Address 1 c/o Ohr Pharmaceutical, Inc. City New York	State/Province/C NEW YORK ive Officer First Name Sam State/Province/C	A89 Fifth Avenu Country Director Street Address 2 489 Fifth Avenu	ZIP/Postal Code 10017 Promoter Middle Name 1c, 28th Floor ZIP/Postal Code				

4. Industry Group

_ A	griculture	0020	lth Care	9	0	Retailing	
	anking & Financial Services	0	Biotechnology			Restaurants	
(Commercial Banking	1.7	Health Insurance		Sur:		
	Insurance	C	Hospitals & Physician	ns		Technology	
(Investing	0	Pharmaceuticals			Computers	
(Investment Banking	()	Other Health Care			C Telecommunications	
(Pooled Investment Fund					C Other Technology	
(Other Banking & Financial Services					Travel	
∩ B	usiness Services	Mai	nufacturing			C Airlines & Airports	
	nergy	Rea	l Estate			C Lodging & Conventions	
	Coal Mining	O	Commercial			C Tourism & Travel Services	
	Electric Utilities	0	Construction REITS & Finance		_	C Other Travel	
	Energy Conservation Environmental Services	Ö			0	Other	
	Oil & Gas	O	Other Real Estate				
(Other Energy						
5. I	ssuer Size						
	ue Range		Aggregate No			_	
•	No Revenues		7040			et Asset Value	
0	\$1 - \$1,000,000		14	\$5,000,00			
0	\$1,000,001 - \$5,000,000		-	00,001 - \$2			
0	\$5,000,001 - \$25,000,000		100	000,001 -			
0	\$25,000,001 - \$100,000,000		7.20			00,000,000	
0	Over \$100,000,000		7.2	\$100,000			
0	Decline to Disclose		14	ine to Dis		se	
0	Not Applicable		C Not A	Applicabl	e		
6. F	Federal Exemption(s) a oly)	nd	Exclusion(s)	Claim	е	d (select all that	
П	Rule 504(b)(1) (not (i), (ii)	Г	Rule 505		_		
	or (iii))	-					
	Rule 504 (b)(1)(i)	14	Rule 506(b)				
	Rule 504 (b)(1)(ii)		Rule 506(c)				
	Rule 504 (b)(1)(iii)	L	Securities Act Section	4(a)(5)			
			Investment Company	Act Sect	ion	3(c)	
7. ¯	Гуре of Filing						
V	New Notice Date of First Sale	20	13-10-02	П	ret	t Sale Yet to Occur	
	Date of First Sale		15 10 02		11 5	Said Tet to Occur	
	Amendment						
8 [Duration of Offering						
				-	2		
Does	the Issuer intend this offering to last mo	ore th	an one year?	*		Yes No No	
9. 7	Гуре(s) of Securities Of	fer	ed (select all	that a	р	ply)	
	Pooled Investment Fund	quity					
20.00	Interests Fenant-in-Common Securities D	ebt					

☐ Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? $_{\rm Yes}$ $_{\rm No}$
Clarification of Response (if Necessary)
11. Minimum Investment
Minimum investment accepted from any outside investor USD
investor
12. Sales Compensation
Recipient Recipient CRD Number None
(Associated) Broker or Dealer None (Associated) Broker or Dealer CRD None Number
Street Address 1 Street Address 2
City State/Province/Country ZIP/Postal Code
City State/Province/Country ZIP/Postal Code
State(s) of Solicitation
13. Offering and Sales Amounts
10. Cheffing and Calco / Wilderto
Total Offering Amount \$ 376915 USD
Total Amount Sold \$ 376915 USD
Total Remaining to be Sold USD Indefinite
Clarification of Response (if Necessary)
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finders' Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known provide an estimate and check the box post to the amount
expenditure is not known, provide an estimate and check the box next to the amount. Sales Commissions \$ 0 USD Estimate

Finders' Fees \$	USI	Estin	nate
Clarification of Response (if Necessary)			
16. Use of Proceeds			
Provide the amount of the gross proceeds of any of the persons required to be named as If the amount is unknown, provide an estin	s executive officers, directors or	promoters in respon	
	\$ 0	USD	Estimate
Clarification of Response (if Necessary)			

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offeroes
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Ohr Pharmaceutical Inc	/s/ Sam Backenroth	Sam Backenroth	CFO & VP of Bus. Development	2013-10-11